Citations

Clear

25 citation(s) found for "Sj, Pandol".

Abstract 4143006: Systemic Vascular Damage and Cardiac Dysfunction in a Mouse Severe Acute Pancreatitis Model
Du, Aolin, Huo, Yu, zhao, debiao, Fayyaz, Ahmed, Buglioni, Alessia , Sangaralingham, Jeson, Lugea, Aurelia, Waldron, Richard T. , Redfield, Margaret M. , Ji, Baoan , Wang, Ying , Waldron, Richard T , Zhang, Junmeng , zhao, debiao, Pandol, Stephen J.

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4143006 Get It

Background and Objective: Decline of cardiovascular (CV) function is commonly observed in patients with severe acute pancreatitis (AP), which is associated with high mortality and morbidity. While the pathological changes in the pancreas during severe AP have been extensively studied, the impact on the CV system has not been well characterized. Furthermore, obesity is a major risk factor for severe AP. Hereby we utilized an obesity-associated mouse AP model to assess potential alterations in vascular integrity and cardiac function, two major components of circulatory failure. Methods: Wild-type male C57BL6J mice were fed a normal or a high fat (to induce obesity) diet. Both groups received intraperitoneal injection of cerulein (100 mg/kg/h x12) to induce AP. H&E and TUNEL staining of pancreas were performed to assess histology and cell death. To measure vascular integrity, we measured the leakiness of a fluorescein-conjugated dextran (70 kDa) in tissue parenchyma and serum levels of soluble vascular endothelial (VE)-cadherin, which has recently shown to be shed from endothelial cells with disrupted adherens junctions. Cardiac systolic and diastolic function were assessed by echocardiography at baseline and post-AP induction. Results: Compared to lean mice, obese mice developed more severe pancreatic edema, cell death and inflammatory cell infiltration, along with significantly increased accumulation of fluorescent dextran in multiple organs including pancreas, heart, lung, and kidney, suggesting systemic disruption of vascular integrity. Increased serum levels of soluble VE-cadherin in obese mice (vs. lean) after AP induction further supported compromised endothelial cell barrier function. At baseline, obese mice exhibited similar cardiac function to lean mice. However, obese mice, but not lean mice, developed impaired systolic and diastolic function post-AP induction, as supported by decreased ejection fraction and e’ velocity respectively. Conclusion: In this obesity-associated severe AP mouse model, systemic vascular permeability is increased, and cardiac function is substantially compromised. Systemic vascular hyperpermeability and cardiac dysfunction may represent therapeutic targets to enhance the outcomes in severe AP.
Association of Serum Endocannabinoid Levels with Pancreatitis and Pancreatitis-Related Pain
Goodman, Marc T. , Lombardi, Christina , Torrens, Alexa , Saloman, Jami L. , Yang, Yunlong, Fisher, William E., Fogel, Evan L. , Forsmark, Christopher E. , Conwell, Darwin L. , Hart, Phil A. , Park, Walter G. , Topazian, Mark, Vege, Santhi Swaroop , Andersen, Dana K. , Yadav, Dhiraj , Goodman, Marc T , Vege, Santhi S, Saloman, Jami L , Bresee, Catherine J. , Li, Liang , Forsmark, Chris E. , Conwell, Darwin L. , Van Den Eeden, Stephen K , Bellin, Melena D. , Serrano, José , Pandol, Stephen J. , Piomelli, Daniele

Mayo Clinic

Cannabis & Cannabinoid Research | September 18, 2024 | Volume: 10 | Issue: 1 | Pages: 60-70

10.1089/can.2024.0079 | PMID 39291350 Get It

Background and Aims: This investigation examined the association of pancreatitis and pancreatitis-related pain with serum levels of two endocannabinoid molecules such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG) and two paracannabinoid molecules such as oleoylethanolamide (OEA) and palmitoylethanolamide (PEA). Methods: A case–control study was conducted within the Prospective Evaluation of Chronic Pancreatitis for Epidemiological and Translational Studies, including participants with no pancreas disease ( N = 56), chronic abdominal pain of suspected pancreatic origin or indeterminate chronic pancreatitis (CP) ( N = 22), acute pancreatitis ( N = 33), recurrent acute pancreatitis ( N = 57), and definite CP ( N = 63). Results: Circulating AEA concentrations were higher in women than in men ( p = 0.0499), and PEA concentrations were higher in obese participants than those who were underweight/normal or overweight ( p = 0.003). Asymptomatic controls with no pancreatic disease had significantly ( p = 0.03) lower concentrations of AEA compared with all disease groups combined. The highest concentrations of AEA were observed in participants with acute pancreatitis, followed by those with recurrent acute pancreatitis, chronic abdominal pain/indeterminant CP, and definite CP. Participants with pancreatitis reporting abdominal pain in the past year had significantly ( p = 0.04) higher concentrations of AEA compared with asymptomatic controls. Levels of 2-AG were significantly lower ( p = 0.02) among participants reporting abdominal pain in the past week, and pain intensity was inversely associated with concentrations of 2-AG and OEA. Conclusions: Endocannabinoid levels may be associated with stage of pancreatitis, perhaps through activation of the CB1 receptor. Validation of our findings would support the investigation of novel therapeutics, including cannabinoid receptor-1 antagonists, in this patient population.
Multiparametric MRI Scoring System of the Pancreas for the Diagnosis of Chronic Pancreatitis
Tirkes, Temel , Yadav, Dhiraj , Conwell, Darwin L. , Zhao, Xuandong, Dasyam, Anil K. , Halappa, Vivek Gowdra, Patel, Aashish, Shah, Zarine K. , Swensson, Jordan , Takahashi, Naoki , Wachsman, Ashley, Yang, Yunlong, Hart, Phil A. , Park, Walter G. , Vege, Santhi Swaroop , Topazian, Mark , Territo, Paul R. , Persohn, Scott A., Andersen, Dana K. , Fogel, Evan L. , Venkatesh, Sudhakar K , Takahashi, Naoki , Dasyam, Anil K , Venkatesh, Sudhakar K. , Li, Liang , Jennings, Kristofer , Pandol, Stephen J.

Mayo Clinic

Journal of Magnetic Resonance Imaging | September 3, 2024 | Volume: 61 | Issue: 5 | Pages: 2183-2194

10.1002/jmri.29594 | PMID 39225586 Get It

BackgroundDuctal features alone may not offer high diagnostic sensitivity or most accurate disease severity of chronic pancreatitis (CP).PurposeDiagnose CP based on multiparametric MRI and MRCP features.Study TypeProspective.PopulationBetween February 2019 and May 2021, 46 control (23 males, 49.3 ± 14.1 years), 45 suspected (20 males, 48.7 ± 12.5 years), and 46 definite (20 males, 53.7 ± 14.6 years) CP patients were enrolled at seven hospitals enrolled in the MINIMAP study. CP classification was based on imaging findings and clinical presentation.Field Strength and Sequences1.5 T. T1‐weighted (T1W) spoiled gradient echo, T1 map with variable flip angle, dual‐echo Dixon, secretin‐enhanced MRCP before and after secretin infusion.AssessmentDual‐echo fat fraction (FF), T1 relaxation time, extracellular volume (ECV), T1 signal intensity ratio of the pancreas to the spleen (T1 score), arterial‐to‐venous enhancement ratio (AVR), pancreatic tail diameter (PTD), pancreas volume, late gadolinium enhancement, pancreatic ductal elasticity (PDE), and duodenal filling grade of secretin‐enhanced MRCP were measured.Statistical TestsLogistic regression analysis generated CP‐MRI and secretin‐enhanced CP‐SMRI scores. Receiver operating characteristics analysis was used to differentiate definite CP from control. Interobserver agreement was assessed using Lin's concordance correlation coefficient.ResultsCompared to control, definite CP cohort showed significantly higher dual‐echo FF (7% vs. 11%), lower AVR (1.35 vs. 0.85), smaller PTD (2.5 cm vs. 1.95 cm), higher ECV (28% vs. 38%), and higher incidence of PDE loss (6.5% vs. 50%). With the cut‐off of >2.5 CP‐MRI score (dual‐echo FF, AVR, and PTD) and CP‐SMRI score (dual‐echo FF, AVR, PTD, and PDE) had cross‐validated area under the curves of 0.84 (sensitivity 87%, specificity 68%) and 0.86 (sensitivity 89%, specificity 67%), respectively. Interobserver agreement for both CP‐MRI and CP‐SMRI scores was 0.74.ConclusionThe CP‐MRI and CP‐SMRI scores yielded acceptable performance and interobserver agreement for the diagnosis of CP.Evidence Level1Technical EfficacyStage 2
Evaluation of Chronic Pancreatitis Prognosis Score in an American Cohort
Conwell, Darwin L. , Hart, Phil A. , Li, Shuang , Stello, Kimberly, Fogel, Evan L. , Fisher, William E., Forsmark, Christopher E., Park, Walter G. , Topazian, Mark , Vege, Santhi Swaroop , Yadav, Dhiraj , Saloman, Jami L. , Saloman, Jami L , Park, Soo Kyoung , Pandol, Stephen J. , Serrano, Jose, Van Den Eeden, Stephen K , Liang, Li

Mayo Clinic

Clinical and Translational Gastroenterology | August 13, 2024 | Volume: 15 | Issue: 11 | Pages: e00758

10.14309/ctg.0000000000000758 | PMID 39137098 Get It

INTRODUCTION: Chronic Pancreatitis Prognosis Score (COPPS) was developed to discriminate disease severity and predict risk for future hospitalizations. In this cohort study, we evaluated if COPPS predicts the likelihood of hospitalization(s) in an American cohort. METHODS: The Chronic Pancreatitis, Diabetes, and Pancreatic Cancer consortium provided data and serum from subjects with chronic pancreatitis (N = 279). COPPS was calculated with baseline data and stratified by severity (low, moderate, and high). Primary endpoints included number and duration of hospitalizations during 12-month follow-up. RESULTS: The mean ± SD COPPS was 8.4 ± 1.6. COPPS correlated with all primary outcomes: hospitalizations for any reason (number: r = 0.15, P = 0.01; duration: r = 0.16, P = 0.01) and pancreas-related hospitalizations (number: r = 0.15, P = 0.02; duration: r = 0.13, P = 0.04). The severity distribution was 13.3% low, 66.0% moderate, and 20.8% high. 37.6% of subjects had ≥1 hospitalization(s) for any reason; 32.2% had ≥1 pancreas-related hospitalizations. All primary outcomes were significantly different between severity groups: hospitalizations for any reason (number, P = 0.004; duration, P = 0.007) and pancreas-related hospitalizations (number, P = 0.02; duration, P = 0.04). The prevalence of continued drinking at follow-up ( P = 0.04) was higher in the low and moderate groups. The prevalence of anxiety at enrollment ( P = 0.02) and follow-up ( P < 0.05) was higher in the moderate and high groups. DISCUSSION: Statistically, COPPS significantly correlated with hospitalization outcomes, but the correlations were weaker than in previous studies, which may be related to the outpatient nature of the PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies cohort and lower prevalence of high severity disease. Studies in other prospective cohorts are needed to understand the full utility of COPPS as a potential tool for clinical risk assessment and intervention.
Systemic Neutrophil Gelatinase-Associated Lipocalin Alterations in Chronic Pancreatitis: A Multicenter, Cross-Sectional Study
Torok, Molly, Pfau, Timothy, Mace, Thomas A. , Cole, Rachel M. , Hart, Phil A. , Krishna, Somashekar G. , Lara, Luis F. , Ramsey, Mitchell L. , Fogel, Evan L. , Forsmark, Chris E. , Li, Liang , Park, Walter G. , Vege, Santhi Swaroop , Yadav, Dhiraj , Conwell, Darwin L. , Cruz‐Monserrate, Zobeida , Krishna, Somashekar G , Gumpper, Kristyn , Chasser, Kaylin M. , Pita-Grisanti, Valentina , Belury, Martha Ann , Culp, Stacey , Fisher, William P. , Pandol, Stephen J. , Serrano, José , Van Den Eeden, Stephen K

Mayo Clinic

Clinical and Translational Gastroenterology | January 29, 2024 | Volume: 15 | Issue: 4 | Pages: e00686

10.14309/ctg.0000000000000686 | PMID 38284831 Get It

INTRODUCTION: Chronic pancreatitis (CP) is a progressive fibroinflammatory disorder lacking therapies and biomarkers. Neutrophil gelatinase-associated lipocalin (NGAL) is a proinflammatory cytokine elevated during inflammation that binds fatty acids (FAs) such as linoleic acid. We hypothesized that systemic NGAL could serve as a biomarker for CP and, with FAs, provide insights into inflammatory and metabolic alterations. METHODS: NGAL was measured by immunoassay, and FA composition was measured by gas chromatography in plasma (n = 171) from a multicenter study, including controls (n = 50), acute and recurrent acute pancreatitis (AP/RAP) (n = 71), and CP (n = 50). Peripheral blood mononuclear cells (PBMCs) from controls (n = 16), AP/RAP (n = 17), and CP (n = 15) were measured by cytometry by time-of-flight. RESULTS: Plasma NGAL was elevated in subjects with CP compared with controls (area under the curve [AUC] = 0.777) or AP/RAP (AUC = 0.754) in univariate and multivariate analyses with sex, age, body mass index, and smoking (control AUC = 0.874; AP/RAP AUC = 0.819). NGAL was elevated in CP and diabetes compared with CP without diabetes ( P < 0.001). NGAL + PBMC populations distinguished CP from controls (AUC = 0.950) or AP/RAP (AUC = 0.941). Linoleic acid was lower, whereas dihomo-γ-linolenic and adrenic acids were elevated in CP ( P < 0.05). Linoleic acid was elevated in CP with diabetes compared with CP subjects without diabetes ( P = 0.0471). DISCUSSION: Elevated plasma NGAL and differences in NGAL + PBMCs indicate an immune response shift that may serve as biomarkers of CP. The potential interaction of FAs and NGAL levels provide insights into the metabolic pathophysiology and improve diagnostic classification of CP.
Circulating immune signatures across clinical stages of chronic pancreatitis: a pilot study
Hagn-Meincke, Rasmus , Hart, Phil A. , Andersen, Dana K. , Vege, Santhi Swaroop , Fogel, Evan L. , Topazian, Mark , Conwell, Darwin L. , Li, Liang , Drewes, Asbjørn Mohr , Forsmark, Chris E. , Fisher, William E., Yadav, Dhiraj , Olesen, Søren Schou , Park, Walter G. , Vege, Santhi S, Serrano, José , Bellin, Melena D. , Van Den Eeden, Stephen K , Pandol, Stephen J.

Mayo Clinic

European Journal of Gastroenterology & Hepatology | December 4, 2023 | Volume: 36 | Issue: 2 | Pages: 177-183

10.1097/meg.0000000000002691 | PMID 38047728 Get It

Objective This pilot study seeks to identify serum immune signatures across clinical stages of patients with chronic pancreatitis (CP). Methods We performed a cross-sectional analysis of prospectively collected serum samples from the PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translation StuDies-study. CP subjects were categorised into three clinical stages based on the presence/absence of metabolic complications: (1) CP with no diabetes and exocrine pancreatic dysfunction (EPD), (2) CP with either diabetes or EPD, and (3) CP with diabetes and EPD. Blinded samples were analysed using an 80-plex Luminex assay of cytokines/chemokines/adhesion molecules. Group and pairwise comparisons were performed to characterise immune signatures across CP subgroups. Results A total of 135 CP subjects (evenly distributed between clinical stages) and 50 controls were studied. Interleukin-6 (IL-6), interleukin-8 (IL-8), and soluble intercellular adhesion molecule 1 (sICAM-1) were significantly elevated in CP subjects compared to controls. The levels of IL-6 and IL-8 increased with advancing disease stages, with the highest levels observed in CP with diabetes and EPD (clinical stage 3). Furthermore, hepatocyte growth factor and macrophage-derived chemokine were significantly increased in clinical stage 3 compared to controls. Conclusion Our study reveals a progressive elevation in pro-inflammatory cytokines and chemokines with advancing clinical stages of CP. These findings indicate potential targets for the development of disease-modifying interventions.
Salivary Biomarker Evaluation of Chronic Pancreatitis Patients Reveals Alterations in Human Proteins, Cytokines, Prostaglandin E2 Levels, and Bacterial Diversity
Waldron, Richard T. , Jones, Elaina K. , Anani, Vincent, Hines, Jolaine M., Lugea, Aurelia, Diniz, Márcio A. , Kim, Sungjin , Habtezion, Aida , Hoffman, Kristi L. , Petrosino, Joseph F. , Fisher, William E., Li, Liang , Lennon, Ryan J. , Vege, Santhi Swaroop , Topazian, Mark , Zhao, Jing , Singh, Ravinder Jit, Diniz, Marcio A , Waldron, Richard T , Zhao, Jing , Lennon, Ryan J. , Singh, Ravinder J. , Pandol, Stephen J.

Mayo Clinic

Pancreas | November 17, 2022 | Volume: 51 | Issue: 7 | Pages: 723-732

10.1097/mpa.0000000000002113 | PMID 36395395 Get It

Objectives Chronic pancreatitis (CP) is a chronic fibroinflammatory condition of the pancreas difficult to diagnose in early stages. Novel biomarkers useful to facilitate early diagnosis or treatment responses may be found in biofluids. Although saliva can be easily and noninvasively collected from patients, useful salivary biomarkers from CP patients have not yet been identified. Methods Here, we analyzed the proteome by quantitative proteomics, cytokine/chemokine levels by Luminex analysis, prostaglandin E2 (PGE2) levels by a mass spectrometry-based assay, and bacterial species diversity by 16S ribosomal ribonucleic acid sequencing in saliva samples from confirmed CP patients and healthy controls. Results Our results indicate the presence of various differentially expressed proteins, cytokines/chemokines, and a loss of oral bacterial diversity in the saliva of CP patients. The PGE2 levels trend toward elevation in CP patients. Area under the receiver operating characteristic curve models for proteomic, cytokine, and PGE2 assays ranged from 0.59 to 0.90. Conclusions Collectively, our studies identify a range of putative CP biomarkers and alterations in human saliva requiring further validation. The biomarker discovery approaches we used might lead to identification of biomarkers useful for CP diagnosis and monitoring.
Rationale and Design for the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study
Hart, Phil A. , Park, Walter G. , Dyer, Anne‐Marie , Andersen, Dana K. , Buxbaum, James , Conwell, Darwin L. , Dungan, Kathleen , Easler, Jeffrey J. , Fogel, Evan L. , Greenbaum, Carla J. , Kalyani, Rita R. , Korc, Murray , Kozarek, Richard A. , Laughlin, Maren R. , Lee, Peter J. , Maranki, Jennifer , Speake, Cate, Toledo, Frederico G. S. , Trikudanathan, Guru , Vege, Santhi Swaroop , Yazıcı, Cemal , Zaheer, Atif , Forsmark, Christopher E., Yadav, Dhiraj , Papachristou, Georgios I. , Chinchilli, Vernon M , Afghani, Elham , Akshintala, Venkata S. , Pandol, Stephen J. , Phillips, Anna Evans , Serrano, José , Singh, Vikesh K. , Speake, Cate , Tirkes, Temel , Wang, Ming , Bellin, Melena D.

Mayo Clinic

Pancreas | October 7, 2022 | Volume: 51 | Issue: 6 | Pages: 568-574

10.1097/mpa.0000000000002079 | PMID 36206460 Get It

Abstract Acute pancreatitis (AP) is a disease characterized by an acute inflammatory phase followed by a convalescent phase. Diabetes mellitus (DM) was historically felt to be a transient phenomenon related to acute inflammation; however, it is increasingly recognized as an important late and chronic complication. There are several challenges that have prevented precisely determining the incidence rate of DM after AP and understanding the underlying mechanisms. The DREAM (Diabetes RElated to Acute Pancreatitis and its Mechanisms) Study is a prospective cohort study designed to address these and other knowledge gaps to provide the evidence needed to screen for, prevent, and treat DM after AP. In the following article, we summarize literature regarding the epidemiology of DM after AP and provide the rationale and an overview of the DREAM study.
Characterizing mechanism-based pain phenotypes in patients with chronic pancreatitis: a cross-sectional analysis of the PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies
Saloman, Jami L. , Conwell, Darwin L. , Fogel, Evan L. , Vege, Santhi Swaroop , Li, Liang , Andersen, Dana K. , Fisher, William E., Forsmark, Christopher E., Hart, Phil A. , Park, Walter G. , Topazian, Mark , Yadav, Dhiraj , Saloman, Jami L , Li, Shuang , Pandol, Stephen J. , Phillips, Anna Evans , Van Den Eeden, Stephen K , Serrano, José

Mayo Clinic

Pain | June 8, 2022 | Volume: 164 | Issue: 2 | Pages: 375-384

10.1097/j.pain.0000000000002710 | PMID 36149018 Get It

Abstract Pain is common in chronic pancreatitis (CP) and profoundly reduces quality of life (QoL). Multiple underlying mechanisms contribute to a heterogenous pain experience and reduce efficacy of pain management. This study was designed to characterize the distribution of mechanism-based pain phenotypes in painful CP. The data analyzed were collected as part of the PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies, an NCI/NIDDK-funded longitudinal study of the natural history of CP. The PROspective Evaluation of Chronic pancreatitis for EpidEmiologic and translational stuDies includes patient-reported outcome (PRO) measures of pain, medication use, global health, and QoL. Of subjects (N = 681) with CP, 80% experienced abdominal pain within the year before enrollment. Subjects who experienced pain in the week before enrollment (N = 391) completed PROMIS Neuropathic and Nociceptive Pain Quality instruments which were then used to classify them by pain type: 40% had nociceptive, 5% had neuropathic-like, and 32% had both types of pain. The prevalence of having both types of pain was higher among women and subjects with diabetes mellitus, whereas nociceptive-only pain was more prevalent among men and those with pancreatic duct stricture. Other factors, including pain medication use and healthcare utilization, did not differ between groups based on pain type. Subjects in the Both group had significantly worse health and QoL scores relative to those with nociceptive-only pain, suggesting that using psychosocial pain surveys may be useful for understanding pain subtypes in patients with CP. Additional research is needed to identify biochemical and biophysical signatures that may associate with and predict responses to mechanism-specific interventions.
Genetic Risk Score in Diabetes Associated With Chronic Pancreatitis Versus Type 2 Diabetes Mellitus
Goodarzi, Mark O. , Nagpal, Tanvi, Greer, Phil J. , Cui, Jinrui, Chen, Yii‐Der I., Pankow, James S. , Rotter, Jerome I. , Alkaade, Samer, Amann, Stephen T. , Baillie, John , Banks, Peter A. , Conwell, Darwin L. , Coté, Gregory A. , Forsmark, Christopher E., Gardner, Timothy B. , Gelrud, Andrés , Guda, Nalini M. , LaRusch, Jessica, Lewis, Michele D. , Money, Mary E. , Muniraj, Thiruvengadam , Romagnuolo, Joseph , Sandhu, Bimaljit S., Sherman, Stuart , Wilcox, C. Mel, Park, Walter G. , Andersen, Dana K. , Hart, Phil A. , Yadav, Dhiraj , Whitcomb, David C. , Whitcomb, David C , Rotter, Jerome I , Pankow, James S , Lewis, Michele D , Nagpal, Tanvi, Guo, Xiuqing , Brand, Randall E. , Papachristou, Georgios I. , Singh, Vikesh K. , Pandol, Stephen J. , Bellin, Melena D.

Mayo Clinic

Clinical and Translational Gastroenterology | June 22, 2019 | Volume: 10 | Issue: 7 | Pages: e00057

10.14309/ctg.0000000000000057 | PMID 31232720 Get It

Introduction: Diabetes mellitus (DM) is a complication of chronic pancreatitis (CP). Whether pancreatogenic diabetes associated with CP-DM represents a discrete pathophysiologic entity from type 2 DM (T2DM) remains uncertain. Addressing this question is needed for development of specific measures to manage CP-DM. We approached this question from a unique standpoint, hypothesizing that if CP-DM and T2DM are separate disorders, they should be genetically distinct. To test this hypothesis, we sought to determine whether a genetic risk score (GRS) based on validated single nucleotide polymorphisms for T2DM could distinguish between groups with CP-DM and T2DM. Methods: We used 60 T2DM single nucleotide polymorphisms to construct a weighted GRS in 1,613 subjects from the North American Pancreatitis Study 2 and 2,685 subjects from the Multi-Ethnic Study of Atherosclerosis, all of European origin. Results: The mean GRS was identical between 321 subjects with CP-DM and 423 subjects with T2DM (66.53 vs 66.42, P = 0.95), and the GRS of both diabetic groups was significantly higher than that of nondiabetic controls (n = 3,554, P < 0.0001). Exploratory analyses attempting to enrich the CP-DM group for pancreatogenic diabetes, such as eliminating diabetes diagnosed before CP, requiring pancreas-specific comorbidities, or removing those with a family history of diabetes, did not improve the ability of the GRS to distinguish between CP-DM and T2DM. Discussion: Recognizing that we lacked a gold standard to define CP-DM, our study suggests that CP-DM may be a subtype of T2DM, a notion that should be tested in future, large prospective studies.